Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

BACKGROUND: Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations. Two cardiovascular (CV) outcomes trials showed that in subjects with T2D at high risk of CV events there were fewer major adverse CV events...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Diabetol
Autors principals: Husain, Mansoor, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7526237/
https://ncbi.nlm.nih.gov/pubmed/32998732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01106-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars